Bang-Lin Wan
Merck & Co., Inc., Rahway, NJ, USA (United States)(US)
Publications by Year
Research Areas
HIV/AIDS drug development and treatment, HIV Research and Treatment, Biochemical and Molecular Research, Hepatitis C virus research, Coagulation, Bradykinin, Polyphosphates, and Angioedema
Most-Cited Works
- → Discovery of Vaniprevir (MK-7009), a Macrocyclic Hepatitis C Virus NS3/4a Protease Inhibitor(2010)176 cited
- → Molecular Modeling Based Approach to Potent P2−P4 Macrocyclic Inhibitors of Hepatitis C NS3/4A Protease(2008)134 cited
- → Discovery of 3-{5-[(6-Amino-1H-pyrazolo[3,4-b]pyridine-3-yl)methoxy]-2-chlorophenoxy}-5-chlorobenzonitrile (MK-4965): A Potent, Orally Bioavailable HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitor with Improved Potency against Key Mutant Viruses(2008)132 cited
- → The design and synthesis of diaryl ether second generation HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) with enhanced potency versus key clinical mutations(2008)61 cited
- → Non-peptide calcitonin gene-related peptide receptor antagonists from a benzodiazepinone lead(2006)52 cited
- → Cyclopropylamino Acid Amide as a Pharmacophoric Replacement for 2,3-Diaminopyridine. Application to the Design of Novel Bradykinin B1 Receptor Antagonists(2006)41 cited
- → Design and Synthesis of Conformationally Constrained Inhibitors of Non-Nucleoside Reverse Transcriptase(2011)41 cited
- → Substituted tetrahydroquinolines as potent allosteric inhibitors of reverse transcriptase and its key mutants(2009)39 cited
- → Biaryl Ethers as Novel Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Key Mutant Viruses(2009)36 cited
- → Neuronopathic GBA1L444P Mutation Accelerates Glucosylsphingosine Levels and Formation of Hippocampal Alpha-Synuclein Inclusions(2022)35 cited